Back

Empagliflozin reduces extracellular volume and myocardial sodium content in patients with heart failure and preserved ejection fraction and correlates with reverse cardiac remodeling (EMPAG CMR-HF)

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Insights in cardiac magnetic resonance heart failure imaging Extracellular Volume ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Carlos Andres Plata Mosquera

HM Nou Delfos Hospital-Comprehensive Centre for Cardiovascular Diseases (CIEC), Barcelona (Spain)

5 More presentations in this session

Presentation thumbnail
Exercise cardiopulmonary magnetic resonance imaging unmasks worsening cardiovascular haemodynamics in the spectrum of heart failure with preserved ejection fraction (HFpEF)
Doctor S. Ng (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Left atrial-to-left ventricular indexed volume ratio: a potential prognostic marker for adverse outcomes in patients with heart failure and reduced left ventricular ejection fraction
Doctor L. Sensini (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Prognostic value of late gadolinium enhancement on cardiovascular magnetic resonance for noncompaction cardiomyopathy patients
Mr M. Tukker (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance imaging in patients with premature ventricular complexes or non-sustained ventricular tachycardia: real-world experience
Doctor K. Gupta (Detroit, US)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance-derived left atrioventricular coupling index for prognostic stratification in patients with reduced ejection fraction: insights from the DERIVATE Registry
Doctor M. Ciarlantini (Bologna, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Insights in cardiac magnetic resonance heart failure imaging

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Effects of early empagliflozin in acute decompensated HFrEF on ventricular systolic and diastolic parameters: interaction with endothelial function and arterial stiffness

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources